- Home
- AKYA vs ADAP Comparison
AKYA vs ADAP Comparison
Compare AKYA & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKYA
- ADAP
- Stock Information
- Founded
- AKYA 2015
- ADAP 2008
- Country
- AKYA United States
- ADAP United Kingdom
- Employees
- AKYA N/A
- ADAP N/A
- Industry
- AKYA Medical Specialities
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- AKYA Industrials
- ADAP Health Care
- Exchange
- AKYA Nasdaq
- ADAP Nasdaq
- Market Cap
- AKYA 145.5M
- ADAP 158.6M
- IPO Year
- AKYA 2021
- ADAP 2015
- Fundamental
- Price
- AKYA $3.02
- ADAP $0.57
- Analyst Decision
- AKYA Buy
- ADAP Strong Buy
- Analyst Count
- AKYA 7
- ADAP 4
- Target Price
- AKYA $4.40
- ADAP $2.79
- AVG Volume (30 Days)
- AKYA 1.2M
- ADAP 2.2M
- Earning Date
- AKYA 03-03-2025
- ADAP 03-05-2025
- Dividend Yield
- AKYA N/A
- ADAP N/A
- EPS Growth
- AKYA N/A
- ADAP N/A
- EPS
- AKYA N/A
- ADAP N/A
- Revenue
- AKYA $86,815,000.00
- ADAP $175,041,000.00
- Revenue This Year
- AKYA N/A
- ADAP $204.91
- Revenue Next Year
- AKYA $11.76
- ADAP N/A
- P/E Ratio
- AKYA N/A
- ADAP N/A
- Revenue Growth
- AKYA N/A
- ADAP 146.27
- 52 Week Low
- AKYA $1.88
- ADAP $0.53
- 52 Week High
- AKYA $6.31
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- AKYA 63.45
- ADAP 40.21
- Support Level
- AKYA $2.59
- ADAP $0.55
- Resistance Level
- AKYA $3.10
- ADAP $0.65
- Average True Range (ATR)
- AKYA 0.25
- ADAP 0.05
- MACD
- AKYA 0.04
- ADAP 0.00
- Stochastic Oscillator
- AKYA 65.52
- ADAP 24.84
About AKYA Akoya BioSciences Inc.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.